Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lineage Cell Therapeutics Inc
(NY:
LCTX
)
0.8604
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lineage Cell Therapeutics Inc
< Previous
1
2
3
4
Next >
Lineage Broadens Collaboration With Advanced BioMatrix for HyStem® Cell Drug Delivery Technology
June 02, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
May 05, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
May 03, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at B. Riley Securities 2022 Neuro & Ophthalmology Virtual Investor Conference on April 27, 2022
April 26, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness
April 25, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of VAC2 for the Treatment of Non-small Cell Lung Cancer
April 13, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the NobleCon18 Investor Conference on April 20, 2022
April 11, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC on March 28, 2022
March 24, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss
March 21, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
RG6501 (OpRegen®) Full Phase 1/2a Results to Be Featured at 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Allen C. Ho, M.D., FACS
March 14, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
January 24, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
January 04, 2022
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
December 21, 2021
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the...
Via
FinancialNewsMedia
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
December 20, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
November 30, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
November 10, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
November 15, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
November 03, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
October 26, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
September 20, 2021
From
Lineage Cell Therapeutics
Via
Business Wire
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
October 18, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
September 15, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
September 30, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Announces Appointment of General Counsel
September 01, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
September 13, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
August 12, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
August 10, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
Lineage Cell Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on August 12, 2021
August 05, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy
July 20, 2021
From
Lineage Cell Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.